Wegovy Tablets Vs Injection

If you have been researching weight loss options in the UK, you have almost certainly come across Wegovy tablets and the term WTI, and you might be wondering what it all means and whether it could genuinely help you reach a healthier weight. The landscape of medically supported weight management has shifted dramatically in recent years, and for many people living with obesity or weight-related health conditions, newer treatments like semaglutide have offered something that fad diets simply could not deliver: clinically proven, sustained results. This guide breaks everything down clearly, honestly, and practically, so you can make an informed decision with the support of your healthcare team.

Table of Contents

1. What Is WTI and How Does It Relate to Wegovy?
2. How Wegovy Tablets Work in the Body
3. Who Is Eligible for Wegovy Tablets in the UK?
4. Wegovy Dosing Schedule and WTI Dose Escalation
5. Common Side Effects and How to Manage Them
6. Clinical Evidence: What the Research Actually Shows
7. Key Takeaways
8. When to Seek Professional Advice
9. Scientific References
10. Frequently Asked Questions

What Is WTI and How Does It Relate to Wegovy Tablets?

WTI stands for Weight Treatment Initiation. It is a term used within NHS and private healthcare frameworks to describe the structured, clinician-supervised process of starting a new weight management medication. Far from being a simple prescription hand-off, WTI encompasses a full clinical assessment, eligibility screening, baseline measurements, and a phased dose-escalation plan designed to make starting treatment as safe and effective as possible. When it comes to general health weight management, getting the initiation process right matters enormously.

For most patients in the UK, the WTI process for Wegovy tablets involves several key steps before the first injection is even administered. Your prescriber will review your full medical history, current medications, cardiovascular risk factors, and any contraindications such as a personal or family history of medullary thyroid carcinoma. This level of clinical diligence is what sets medically supervised treatment apart from unregulated alternatives and is a cornerstone of safe semaglutide prescribing in 2026.

Understanding WTI also helps patients set realistic expectations. It makes clear that Wegovy is not a quick fix but a structured, long-term commitment that requires consistent engagement with your care team, lifestyle adjustments, and patience during the dose escalation phase. When patients understand what WTI involves before they start, they are significantly more likely to remain adherent and achieve meaningful, lasting results.

• WTI includes a clinical consultation, BMI check, and medical history review before prescribing
• Baseline measurements such as blood pressure, blood glucose, and weight are recorded at WTI
• The prescriber will identify any contraindications or drug interactions during the WTI assessment
• WTI sets the dose schedule and follow-up review dates from the outset
• Patients are briefed on expected side effects, dietary guidance, and injection technique during WTI

How Wegovy Tablets Work in the Body

Semaglutide, the active ingredient in Wegovy tablets, belongs to a class of medicines known as GLP-1 receptor agonists. GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone released by the gut in response to food. It plays a central role in regulating appetite, gastric emptying, and insulin secretion. In people living with obesity, GLP-1 signalling is often blunted, meaning the normal biological cues that tell the brain "you are full" do not work as effectively as they should. Wegovy tablets replicate and amplify this signalling, essentially restoring a sense of satiety that many patients have been missing for years.

When semaglutide binds to GLP-1 receptors in the brain, particularly in the hypothalamus, it reduces hunger and increases feelings of fullness after smaller portions of food. At the same time, it slows the rate at which food leaves the stomach, which prolongs the sensation of being satisfied after a meal. This dual mechanism helps patients eat less without the constant hunger and cravings that typically derail traditional dieting efforts. For many people, this is the pain point that no amount of willpower or calorie counting could previously overcome.

It is also worth noting that semaglutide has demonstrated benefits beyond weight loss alone. Research has shown improvements in blood pressure, fasting blood glucose, cholesterol profiles, and markers of cardiovascular risk. For patients who come to treatment with comorbidities like type 2 diabetes or hypertension, these secondary benefits can be clinically significant. This is why Wegovy tablets are now positioned not just as a weight loss medication, but as a broader cardiometabolic health intervention.

• Semaglutide activates GLP-1 receptors in the brain and gut to reduce hunger
• Slows gastric emptying, helping patients feel fuller for longer after meals
• Reduces food cravings and compulsive eating behaviours in many patients
• Improves blood glucose control, particularly relevant for patients with prediabetes
• Cardiovascular benefits have been demonstrated in large-scale clinical trials

Who Is Eligible for Wegovy Tablets in the UK?

Eligibility for Wegovy tablets in the UK is based on clinical criteria established by NICE and the Medicines and Healthcare products Regulatory Agency (MHRA). To qualify for semaglutide treatment as a weight management medication, patients must generally have a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above if they have at least one weight-related health condition. Qualifying conditions include type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or non-alcoholic fatty liver disease.

In addition to BMI criteria, patients must not have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), as semaglutide carries a theoretical risk in this context based on animal studies. Patients with a history of pancreatitis, severe gastrointestinal disease, or severe renal impairment should also discuss these factors carefully with their prescriber. Pregnancy and breastfeeding are absolute contraindications, and effective contraception is recommended for women of childbearing age during treatment.

Ethnicity-adjusted BMI thresholds also apply in clinical practice. For South Asian, Chinese, and other at-risk ethnic groups, a lower BMI threshold of 27.5 kg/m² (or 25 kg/m² with a comorbidity) may be used to account for differences in metabolic risk at lower body weights. This nuanced approach reflects current UK guidelines and ensures that treatment reaches the patients most likely to benefit.

• BMI of 30 or above, or 27 or above with a qualifying health condition
• Adjusted thresholds for South Asian, Chinese, and other higher-risk ethnic groups
• Not suitable for those with a history of medullary thyroid carcinoma or MEN2
• Contraindicated in pregnancy and during breastfeeding
• All patients should undergo a full medical review before starting treatment

Wegovy Dosing Schedule and WTI Dose Escalation

One of the most important aspects of the WTI process is understanding the dose escalation schedule. Wegovy tablets are not started at the full therapeutic dose. Instead, patients begin at the lowest dose and increase gradually over 16 to 20 weeks. This is done intentionally to reduce the likelihood and severity of gastrointestinal side effects such as nausea, vomiting, and diarrhoea. Rushing the escalation process is one of the most common reasons patients discontinue treatment prematurely, so the WTI framework is specifically designed to prevent this.

The standard dose escalation for Wegovy begins at 0.25 mg once weekly for the first four weeks. The dose is then increased every four weeks through 0.5 mg, 1 mg, and 1.7 mg, before reaching the target maintenance dose of 2.4 mg once weekly. If a patient experiences intolerable side effects at any stage, the prescriber may recommend staying at the current dose for an additional four weeks before attempting to escalate again. This flexible, patient-centred approach is central to the WTI philosophy and helps maintain long-term adherence.

Wegovy is administered as a subcutaneous injection, typically into the abdomen, thigh, or upper arm. It is given once per week on the same day each week. Patients are trained on self-injection technique during the WTI consultation, and most find the pre-filled pen device easy to use after the first few administrations. The pen comes in different dose strengths corresponding to each stage of the escalation schedule, making it straightforward to follow the prescribed programme.

Week of Treatment	Semaglutide Dose	Phase	Key Clinical Focus
Weeks 1–4	0.25 mg once weekly	WTI Initiation	Tolerability assessment, injection technique training
Weeks 5–8	0.5 mg once weekly	Escalation Phase 1	Appetite suppression begins, GI side effects monitored
Weeks 9–12	1 mg once weekly	Escalation Phase 2	Meaningful weight loss typically begins, blood glucose reviewed
Weeks 13–16	1.7 mg once weekly	Escalation Phase 3	Weight loss accelerates, lifestyle adherence reinforced
Week 17 onwards	2.4 mg once weekly	Maintenance Dose	Long-term weight management, cardiometabolic risk reduction

• Starting dose is always 0.25 mg for the first four weeks regardless of body weight
• Each dose increase occurs every four weeks to allow the body to adapt
• The maintenance dose of 2.4 mg is where the majority of clinical weight loss occurs
• Dose escalation can be paused if side effects are difficult to manage
• Missing a dose by more than five days requires restarting at a lower dose in some cases

Common Side Effects and How to Manage Them

Gastrointestinal side effects are the most frequently reported issue with Wegovy tablets, and they are the primary reason some patients struggle to complete the WTI dose escalation process. Nausea is the most common complaint, affecting a significant proportion of users, particularly during the first few weeks at each new dose level. Vomiting, diarrhoea, constipation, bloating, and acid reflux are also reported. The good news is that for the vast majority of patients, these effects are temporary and tend to resolve as the body adjusts to the medication within two to four weeks of each dose increase.

There are several practical strategies that can make a real difference to tolerability during the WTI phase. Eating smaller, more frequent meals rather than large portions helps significantly. Avoiding high-fat, heavily processed, or spicy foods during the initial weeks reduces nausea. Eating slowly and stopping as soon as you feel satisfied rather than eating until full is also important. Staying well-hydrated throughout the day helps with constipation and diarrhoea. Many patients find that taking their weekly injection in the evening means any transient nausea occurs during sleep and causes minimal disruption to their day.

More serious but rare side effects include pancreatitis, gallbladder problems, and in very rare cases, hypoglycaemia, particularly in patients also taking insulin or sulphonylureas. Any persistent or severe abdominal pain, especially if accompanied by vomiting, should be assessed urgently, as this could indicate pancreatitis. Vision changes, rapid heartbeat, or allergic reactions such as swelling of the face or throat require immediate medical attention. These serious events are uncommon but underscore why ongoing monitoring during WTI and beyond is so important.

• Nausea is the most common side effect and typically improves within two to four weeks at each dose
• Eating smaller meals and avoiding fatty foods significantly reduces gastrointestinal discomfort
• Injecting in the evening can help patients sleep through mild nausea
• Persistent severe abdominal pain should always be investigated urgently
• Report any unusual symptoms to your prescriber promptly, especially during early WTI stages

Clinical Evidence: What the Research Actually Shows

The clinical case for Wegovy tablets is extraordinarily robust by any measure. The STEP (Semaglutide Treatment Effect in People with Obesity) trial programme, which forms the cornerstone of the evidence base, involved more than 4,500 adults across multiple countries including the UK. In the landmark STEP 1 trial, participants who received 2.4 mg semaglutide once weekly alongside lifestyle intervention lost an average of 14.9% of their body weight over 68 weeks, compared to just 2.4% in the placebo group. For a person starting at 100 kg, that represents approximately 15 kg of clinically meaningful weight loss.

Beyond weight, the STEP trials demonstrated statistically significant improvements in waist circumference, systolic blood pressure, fasting blood glucose, HbA1c, and quality of life scores. The SELECT trial, published in 2024 and widely referenced in 2026 clinical guidance, further demonstrated that semaglutide reduced the risk of major adverse cardiovascular events by 20% in overweight and obese adults with established cardiovascular disease but without diabetes. This places Wegovy tablets in a uniquely important position as both a weight management and a cardiovascular risk-reduction tool.

It is important to note that clinical trial results represent averages, and individual outcomes vary based on adherence to lifestyle changes, genetic factors, gut microbiome composition, and baseline metabolic health. Patients who combine semaglutide with a structured dietary approach and regular physical activity consistently achieve better outcomes than those who rely on medication alone. This reinforces the WTI framework's emphasis on lifestyle support alongside pharmacological treatment, ensuring that patients get the very best possible results from their investment in treatment.

• STEP 1 trial showed an average 14.9% body weight reduction over 68 weeks at 2.4 mg semaglutide
• SELECT trial (2024) demonstrated a 20% reduction in major cardiovascular events
• Semaglutide significantly improves blood pressure, cholesterol, and HbA1c alongside weight loss
• Lifestyle support during WTI improves outcomes beyond what medication achieves alone
• Real-world data from 2026 continues to support the safety and efficacy profile seen in trials

Key Takeaways

• WTI (Weight Treatment Initiation) is the structured clinical process for safely starting Wegovy tablets under prescriber supervision in the UK
• Semaglutide works by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and support long-term weight management
• Eligibility is based on BMI criteria and the presence of weight-related health conditions, reviewed carefully during the WTI consultation
• The dose escalation schedule from 0.25 mg to 2.4 mg over 16 to 20 weeks is essential for minimising side effects and maintaining adherence
• Clinical trials demonstrate up to 15% average weight loss over 68 weeks, with additional cardiovascular and metabolic benefits confirmed in 2026 evidence

When to Seek Professional Advice

There are several situations during your Wegovy treatment journey where you should seek professional advice promptly rather than waiting for your next scheduled review. If you experience severe or persistent abdominal pain that does not resolve within a day, particularly if it spreads to your back or is accompanied by vomiting, contact your prescriber or NHS 111 immediately as this may indicate pancreatitis. Similarly, any signs of a serious allergic reaction, including facial swelling, difficulty breathing, or severe skin reactions, require emergency medical attention.

If you notice significant changes in your mood, including depression or thoughts of self-harm, speak to your GP or prescriber without delay. Whilst rare, mood changes have been reported with GLP-1 medications and are taken seriously within clinical guidelines. If your blood sugar drops to an unusually low level and you are taking other diabetes medications alongside Wegovy, seek advice on whether dose adjustments are needed. You should also seek advice if you experience sudden or severe vision changes, as these may indicate rapid improvements in blood glucose affecting your eyes.

On a more routine level, do not hesitate to contact your prescriber if nausea or vomiting is so severe that you are unable to eat or drink, if you are losing weight faster than expected, or if you feel that the treatment is not working despite reaching the maintenance dose. Weight management is a long-term journey, and having an open and ongoing conversation with your healthcare team is one of the most powerful tools you have for success.

Scientific References

1. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. STEP 1 Trial. [Accessed 12 August 2026]
2. National Institute for Health and Care Excellence (NICE). (2023). Semaglutide for managing overweight and obesity. Technology Appraisal Guidance TA875. NICE, UK. [Accessed 12 August 2026]
3. Ryan DH, et al. (2024). SELECT Trial: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The Lancet. [Accessed 12 August 2026]
4. NICE Technology Appraisal TA875: Semaglutide for managing overweight and obesity, NICE, 2023 [Accessed 12 August 2026]
5. Wegovy 2.4 mg solution for injection Summary of Product Characteristics, electronic Medicines Compendium (eMC), Novo Nordisk, 2023 [Accessed 12 August 2026]
6. MHRA: Reclassification of semaglutide (Wegovy) to prescription only medicine, MHRA, 2023 [Accessed 12 August 2026]
7. Wilding JPH et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial), The Lancet, 2021 [Accessed 12 August 2026]
8. Semaglutide treatments: understanding the differences, Diabetes UK, 2023 [Accessed 12 August 2026]
9. Semaglutide drug monograph, British National Formulary (BNF), NICE, 2024 [Accessed 12 August 2026]

Frequently Asked Questions

How long does it take for Wegovy tablets to work?

Wegovy tablets (semaglutide) typically begin to reduce appetite within the first one to two weeks of starting treatment. Meaningful weight loss is usually noticeable after four to eight weeks, with the most significant results seen after 16 to 68 weeks of consistent use alongside a calorie-controlled diet and regular physical activity.

Is Wegovy safe to use long term?

Wegovy (semaglutide) is considered safe for long-term use when prescribed and monitored by a qualified healthcare professional. Clinical trials running up to 68 weeks, and ongoing 2026 real-world data, show a favourable safety profile. Regular reviews with your prescriber are recommended to monitor blood sugar, blood pressure, and overall health.

Can you take Wegovy tablets with other medications?

Wegovy tablets can interact with certain medications, particularly insulin and other diabetes drugs, which may require dose adjustments to avoid hypoglycaemia. Always inform your prescriber of every medication, supplement, and herbal remedy you take before starting semaglutide, so they can review potential interactions and ensure your treatment plan is safe.

What is the starting dose of Wegovy tablets?

The starting dose of Wegovy tablets (semaglutide) is 0.25 mg once weekly for the first four weeks. The dose is then gradually increased every four weeks through 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg, which is the recommended maintenance dose for sustained weight management in eligible adults.